Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable ap...

Miles D., Ciruelos E., Schneeweiss A., Puglisi F., Peretz-Yablonski T., Campone M., Bondarenko I., Nowecki Z., Errihani H., Paluch-Shimon S., Wardley A., Merot J.-L, Trask P., du Toit Y., Pena-Murillo C., Revelant V., Klingbiel D., Bachelot T., Bouzid K., Desmoulins I., Coudert B., Glogowska I., Ciruelos Gil E., Dalenc F., Ricci F., Dieras V., Kaufman B., Ferreira A., Mano M., Kalofonos H., Hitre Erika, Láng István, Horváth Zsolt, Bodoky György, Kahán Zsuzsanna, Kollaborációs szervezet: PERUSE investigators, et al
2021